FA
REGN icon

Fiducient Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Fiducient Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-390
Closed -$219K – 187
2025
Q3 		$219K Hold
390
– – 0.03% 149
2025
Q2 		$205K Hold
390
– – 0.03% 149
2025
Q1 		$247K Sell
390
-17
-4% -$11.7K 0.03% 142
2024
Q4 		$290K Hold
407
– – 0.04% 126
2024
Q3 		$428K Buy
407
+4
+1% +$4.45K 0.05% 96
2024
Q2 		$424K Buy
403
+90
+29% +$87.2K 0.06% 93
2024
Q1 		$301K Buy
+313
New +$298K 0.06% 106

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Fiducient Advisors's REGN Position: Q4 2025 in Review

Fiducient Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 390 shares — an estimated $219K sold.

Fiducient Advisors first reported a position in REGN in Q1 2024 and held it in 7 quarters. The position peaked at $428K in Q3 2024. 1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Fiducient Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Fiducient Advisors sold 390 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $219K.
  • Fiducient Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Fiducient Advisors's Regeneron Pharmaceuticals position peaked at $428K in Q3 2024.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Fiducient Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.